AMAG Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AMAG Pharmaceuticals Inc.
A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs will shut down on 30 September if Congress doesn’t act to renew them – but some US senators say the programs are wasteful and may funnel research overseas.
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Halozyme will pay $960m to acquire Antares, gaining an auto-injector drug delivery platform, which the company said has broad licensing potential, as well as a commercial portfolio.
- Other Names / Subsidiaries
- Advanced Magnetics, Inc.
- Cord Blood Registry (CBR)
- Ethex Corporation
- K-V Pharmaceutical Company (KV Pharmaceutical)
- Lumara Health Inc.
- Perosphere Inc.
- Perosphere Pharmaceuticals
- Ther-Rx Corporation